康聖環球(09960.HK)擬1065.79萬元收購武漢海希生命科技21.77%股權
格隆匯12月1日丨康聖環球(09960.HK)發佈公吿，2021年11月30日，康聖武漢外商獨資企業(康聖環球醫學科技(武漢)有限公司，公司全資附屬公司)與目標公司(即武漢海希生命科技有限公司)、黃士昂醫生及李小青博士訂立股權轉讓協議，內容有關由康聖武漢外商獨資企業以總代價人民幣1065.79萬元收購目標公司的21.77%股本權益。
同日，康聖武漢外商獨資企業、合夥企業(即湖北瑞江康聖產業投資基金合夥企業(有限合夥))、康聖北京外商獨資企業(康聖環球(北京)醫學技術有限公司，公司全資附屬公司)、黃醫生及李小青博士與目標公司訂立增資協議，據此，(其中包括)康聖武漢外商獨資企業及合夥企業各自同意以現金向目標公司出資人民幣1500萬元。待收購事項及增資完成後，目標公司將由公司透過康聖武漢外商獨資企業及康聖北京外商獨資企業持有51.10%，併成為公司的非全資附屬公司。
根據披露，目標公司根據中國法律於2020年8月18日成立，其主要業務為投資控股，並持有海希生物的全部股權。海希生物主要從事試劑耗材的研發、生產及銷售。截至該公吿日期，目標公司由黃醫生持有34%、李小青博士持有36%及康聖北京外商獨資企業持有30%。合夥企業根據中國法律於2021年9月18日成立，截至該公吿日期，武漢布斯為合夥企業的普通合夥人，而康聖武漢投資、鄂州昌達及葛店投資為合夥企業的有限合夥人。
公吿稱，收購事項及增資將對公司及其股東整體有利，因其可鞏固公司對目標集團業務營運及發展的控制及主導；推進和實現集團向臨牀特檢業務上游即試劑研發、生產、銷售發展的戰略；及因公司於目標公司的股權增加而進一步提升公司的盈利能力。同時，增資亦將為目標集團的研發、建設GMP(藥品生產質量管理規範)廠房及註冊體外診斷試劑證提供必要的財務資源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
